Characterization and immunogenicity of meningococcal group C conjugate vaccine prepared using hydrazide-activated tetanus toxoid. (Q51972357)

19 April 2018

title

Characterization and immunogenicity of meningococcal group C conjugate vaccine prepared using hydrazide-activated tetanus toxoid. (English)

1 reference

19 April 2018

10

Frasch CE

1 reference

19 April 2018

author name string

Silveira IA

1

1 reference

19 April 2018

Bastos RC

2

1 reference

19 April 2018

Neto MS

3

1 reference

19 April 2018

Laranjeira AP

4

1 reference

19 April 2018

Assis EF

5

1 reference

19 April 2018

Fernandes SA

6

1 reference

19 April 2018

Leal ML

7

1 reference

19 April 2018

Silva WC

8

1 reference

19 April 2018

Lee CH

9

1 reference

19 April 2018

Peralta JM

11

1 reference

19 April 2018

Jessouroun E

12

1 reference

19 April 2018

language of work or name

English

0 references

publication date

7 August 2007

1 reference

19 April 2018

number of pages

10

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

19 April 2018

volume

25

1 reference

19 April 2018

issue

41

1 reference

19 April 2018

page(s)

7261-7270

1 reference

19 April 2018

cites work

Meningococcal disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.037

Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.037

Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.037

A randomised, double-blind, controlled trial of the immunogenicity and tolerability of a meningococcal group C conjugate vaccine in young British infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.037

Immunologic hyporesponsiveness to serogroup C but not serogroup A following repeated meningococcal A/C polysaccharide vaccination in Saudi Arabia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.037

Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.037

Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.037

Conjugate meningococcal serogroup A and C vaccine: reactogenicity and immunogenicity in United Kingdom infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.037

Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.037

Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.037

Impact of mass vaccination with polysaccharide conjugate vaccine against serogroup C meningococcal disease in Spain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.037

Dramatic decline of serogroup C meningococcal disease in Catalonia (Spain) after a mass vaccination campaign with meningococcal C conjugated vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.037

Meningococcal polysaccharide-protein conjugate vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.037

Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.037

Preparation of pneumococcal capsular polysaccharide-protein conjugate vaccines utilizing new fragmentation and conjugation technologies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.037

Versatile and efficient synthesis of protein-polysaccharide conjugate vaccines using aminooxy reagents and oxime chemistry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.037

Human immunity to the meningococcus. 3. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.037

Quantitative estimation of sialic acids. II. A colorimetric resorcinol-hydrochloric acid method

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.037

Scientific challenges for the quality control and production of group C meningococcal conjugate vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.037

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.037

A rapid formaldehyde assay using purpald reagent: application under periodation conditions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.037

Comparison of the rabbit pyrogen test and Limulus amoebocyte lysate (LAL) assay for endotoxin in hepatitis B vaccines and the effect of aluminum hydroxide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.037

Full 1H NMR assignment and detailed O-acetylation patterns of capsular polysaccharides from Neisseria meningitidis used in vaccine production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.037

Use and validation of NMR assays for the identity and O-acetyl content of capsular polysaccharides from Neisseria meningitidis used in vaccine manufacture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.037

A review of vaccine research and development: meningococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.037

Relationships among physico-chemical and biological tests for a synthetic Hib-TT conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.037

Mucosal immune responses to meningococcal C polysaccharide-protein conjugate in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.037

Construction of designer glycoconjugate vaccines with size-specific oligosaccharide antigens and site-controlled coupling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.037

Memory immune response generated inCercopithecus aethiopsagainst meningococcal polysaccharide serogroup C conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.037

Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.037

Meningococcal surrogates of protection--serum bactericidal antibody activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.037

New meningococcal C polysaccharide-tetanus toxoid conjugate Physico-chemical and immunological characterization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.037

Immunization of female mice with glycoconjugates protects their offspring against encapsulated bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.037

Effect of conjugation methodology on the immunogenicity and protective efficacy of meningococcal group C polysaccharide-P64k protein conjugates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.037

Disparity in functional activity between serum anticapsular antibodies induced in adults by immunization with an investigational group A and C Neisseria meningitidis-diphtheria toxoid conjugate vaccine and by a polysaccharide vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.037

Correlation between the avidity of mouse-human chimeric IgG subclass monoclonal antibodies measured by solid-phase elution ELISA and biospecific interaction analysis (BIA)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.037

Comparison of functional immune responses in humans after intranasal and intramuscular immunisations with outer membrane vesicle vaccines against group B meningococcal disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.037

Antigen persistence is required for somatic mutation and affinity maturation of immunoglobulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.037

Effect of vaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.037

PorA-specific differences in antibody avidity after vaccination with a hexavalent Men B outer membrane vesicle vaccine in toddlers and school children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.037

Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.037

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2007.07.037

1 reference

19 April 2018

1 reference

19 April 2018